AlloSource

How Supplied

Scientific literature consistently lists these potential benefits of skin allograft use on chronic wounds: Minimizes infection and keeps the wound bed mechanically clean; acts as a bacterial barrier; decreases loss of protein, water, and electrolyte; reduces pain; decreases incidence of contractures; may provide a “dose pack” of growth factors to wound bed; prevents desiccation of bone and tendon; stimulates re-epithelialization and wound neovascularization.

SnyderRJ. Treatment of nonhealing ulcers with allografts. Clin Dermatol. 2005;23:388–395

SpenceRJ, WongL. The enhancement of wound healing with human skin allograft. Surg Clin North Am. 1997;77:3,731–745

As a homologous-use allograft (FDA 21 CFR 1271), AlloSkin™ may be used to repair any integumental defect, such as those caused by ulcers and burns, and is appropriate for use over exposed substructures such as bone, tendon, ligament, and muscle.

• The presence of gross infection at the transplantation site is a contraindication for use of skin allografts.

• Ensure wound is adequately debrided and free of infection.

• Place AlloSkin or inner pouch in a sterile basin on a sterile field. Immerse the skin or inner pouch completely in sterile isotonic solution for a minimum of 1 minute and a maximum of 5 minutes until thawed. Avoid “soaking” tissue, as this may cause the dermal and epidermal layers to separate.

• Cryopreserved skin is preserved with 15% Glycerin in LR+ Gentamicin/RPMI 1640. Graft should be rinsed with sterile isotonic solution prior to transplant.

• Apply AlloSkin to wound dermal (shiny) side down. Stretch so graft has contact with all wound contours and trim excess graft to fit wound.

• Anchor graft as appropriate (can staple, suture, steristrip, or tack with silicone dressing) and dress graft as appropriate for amount of exudate and location of wound. Almost any dressing is appropriate for use over AlloSkin graft, including silver dressings and foams. May use in conjunction with NPWT and HBO therapy.

• Inspect wound weekly, sooner if deemed necessary, to determine if AlloSkin is still in place or beginning to slough. Tissue sloughs in 7 to 14 days and wound bed granulation proceeds.

• Depending upon wound assessment, physician may leave graft in place, replace graft with new application of AlloSkin or apply a skin substitute if adequate granulation is present.

Reference

1. DesmanE, BarrowW, AndersonLH. Human Skin allografts for patients with diabetic foot ulcers, venous leg ulcers, or surgical/traumatic wounds: A retrospective, descriptive study. Ostomy Wound Manage. 2015;61(7):16–22.